CLINICAL_TRIALS trial_result · 2017-07-11

Clinical Trial Update: Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v. [Phase 4]

Phase 4 post-authorization safety study of HX575 given intravenously in adults with Chronic Kidney Disease; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Sandoz | Conditions: Chronic Kidney Disease | Phase 4 | Status: COMPLETED | Results posted: 2017-07-11